Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

4    Novartis    $19.2B    up 6.7%


Global revenue:  $58.5B (3rd); up 15.6%

R&D spend: $9.2B (1st), up 13.6%; 15.7% of rev.

Top brands: Diovan/Co-Diovan ($2.3B); Gleevec ($1.5B); Zometa ($642M); Sandostatin ($574M)

Planned launches: Bexsero (men. B vacc.); Seebri Breezhaler (NVA237)/QVA149 (COPD)

Promotional spend: $973M (6th); 5.1% of rev.

Patent expirations: Diovan (2012); Zometa (2013); Gleevec (2015)

Novartis is bracing for some ugly patent exclusivity losses, with ­blockbuster Femara having gone off patent and $2.3-billion Diovan, the company's top seller, facing generic competition in September. Next year, $642-million Zometa goes over the patent cliff, and in 2015, $1.5-billion Gleevec loses exclusivity. But the Swiss giant has cobbled together an Alpine portfolio from steadily-performing smaller brands while diversifying its business into generics (Sandoz), vaccines and diagnostics and, most recently, vision care with its acquisition of Alcon in 2010. The company boasts a muscular R&D operation, as evidenced by MS drug Gilenya, a likely blockbuster approved in 2010, and Arcapta Neohaler for COPD, approved in July, along with a robust late-stage pipeline. However, Novartis has been plagued by manufacturing issues at plants in Quebec and Nebraska. Other potential pitfalls include safety concerns about Gilenya that could hamper that key product's potential, and FDA delays on approvals of the Menveo vaccine and Seebri Breez­haler (NVA237).

Back to first page

Page 4 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.